Regulatory and clinical considerations for biosimilar oncology drugs
- 1 December 2014
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 15 (13) , e594-e605
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Rituximab and biosimilars – equivalence and reciprocityBiosimilars, 2013
- Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factorsExpert Opinion on Drug Safety, 2013
- Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to goJournal of Pharmacy and Bioallied Sciences, 2013
- Biosimilars: what clinicians should knowBlood, 2012
- Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of ImmunogenicityPharmaceutical Research, 2011
- Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor AssociationHaematologica, 2011
- Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow TransplantationHaematologica, 2011
- Biosimilar agents in oncology/haematology: from approval to practiceEuropean Journal of Haematology, 2010
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004